πŸš€ Pharmidex Unveils Its Cutting-Edge In Silico Drug Discovery Platform! πŸ§¬πŸ’»
February 24, 2025

At Pharmidex, we are revolutionizing drug discovery with our state-of-the-art in silico platform (https://lnkd.in/eibfwguP), accelerating the path from target identification to lead optimization with precision and efficiency.

πŸ”¬ What sets our platform apart?
βœ… AI-driven target identification & protein structure analysis
βœ… Advanced molecular docking for high-affinity ligand screening
βœ… 3D pharmacophore modeling for enhanced drug design
βœ… Seamless integration of predictive simulations & real-world validation

Our approach combines cutting-edge computational tools with deep scientific expertise to de-risk drug development and fast-track novel therapeutics for a healthier future.

πŸ“½οΈ Watch our latest video(1/5) showcasing the power of our technology, starting from Determination of target structures and Determination of ligands

πŸ“© Ready to transform your drug discovery journey? Let’s collaborate!

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 30, 2025
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. πŸ‘©‍πŸ”¬ πŸ‘¨‍πŸ”¬ Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion
July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: βœ… Bitter-tasting APIs βœ… Unpalatable excipients βœ… The success of taste-masking strategies βœ… Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
More Posts